Skip to main content
SpringerLink
Log in

Fulvestrant in postmenopausal women with locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy: a guide

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Fulvestrant (Faslodex®) is indicated for the treatment of postmenopausal women with advanced or metastatic breast cancer that has progressed on prior endocrine therapy. A regimen of fulvestrant 500 mg (i.e. 500 mg on days 0, 14 and 28, then 500 mg every 28 days) prolonged the time to disease progression and overall survival to a greater extent than a fulvestrant 250 mg regimen and was generally well tolerated in this patient population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon: International Agency for Research on Cancer; 2015.

  2. Anderson WF, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat. 2002;76(1):27–36.

    Article  CAS  PubMed  Google Scholar 

  3. Suzuki T, Miki Y, Nakamura Y, et al. Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer. 2005;12(4):701–20.

    Article  CAS  PubMed  Google Scholar 

  4. Cardoso F, Harbeck N, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vi11–9.

    Article  Google Scholar 

  5. Milano A, Dal Lago L, Sotiriou C, et al. What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer. 2006;42(16):2692–705.

    Article  CAS  PubMed  Google Scholar 

  6. Faslodex® (fulvestrant) 250 mg injectable solution: Brazilian prescribing information. Cotia: AstraZeneca do Brasil Ltda; 2014.

  7. Faslodex (fulvestrant) 250 mg injectable solution: EU summary of product characteristics. London: European Medicines Agency; 2015.

  8. Faslodex® (fulvestrant) injection: US prescribing information. Wilmington: AstraZeneca Pharmaceuticals LP; 2012.

  9. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol. 2001;28(3):291–304.

    Article  CAS  PubMed  Google Scholar 

  10. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51(15):3867–73.

    CAS  PubMed  Google Scholar 

  11. Wakeling AE, Bowler J. Steroidal pure antioestrogens. J Endocrinol. 1987;112(3):R7–10.

    Article  CAS  PubMed  Google Scholar 

  12. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(Suppl 1):S2–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Glück S. Extending the clinical benefit of endocrine therapy for women with hormone receptor-positive metastatic breast cancer: differentiating mechanisms of action. Clin Breast Cancer. 2014;14(2):75–84.

    Article  PubMed  Google Scholar 

  14. Kuter I, Gee JM, Hegg R, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat. 2012;133(1):237–46.

    Article  CAS  PubMed  Google Scholar 

  15. Robertson JFR, Dixon JM, Sibbering DM, et al. A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. Breast Cancer Res. 2013;15:R18.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. McKeage K, Curran MP, Plosker GL. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Drugs. 2004;64(6):633–48.

    Article  CAS  PubMed  Google Scholar 

  17. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20(16):3396–403.

    Article  CAS  PubMed  Google Scholar 

  18. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20(16):3386–95.

    Article  CAS  PubMed  Google Scholar 

  19. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003;98(2):229–38.

    Article  CAS  PubMed  Google Scholar 

  20. Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005;104(2):236–9.

    Article  CAS  PubMed  Google Scholar 

  21. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26(10):1664–70.

    Article  CAS  PubMed  Google Scholar 

  22. Ohno S, Rai Y, Iwata H, et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results of a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010;21(12):2342–7.

    Article  CAS  PubMed  Google Scholar 

  23. Pritchard KI, Rolski J, Papai Z, et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat. 2010;123(2):453–61.

    Article  CAS  PubMed  Google Scholar 

  24. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–600.

    Article  PubMed  Google Scholar 

  25. Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg versus 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;106(1):djt337.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Mauriac L, Pippen JE, Quaresma Albano J, et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer. 2003;39(9):1228–33.

    Article  CAS  PubMed  Google Scholar 

  27. Mauriac L, Romieu G, Bines J. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial. Breast Cancer Res Treat. 2009;117(1):69–75.

    Article  CAS  PubMed  Google Scholar 

  28. Neven P, Paridaens R, Pelgrims G, et al. Fulvestant (FaslodexTM) in advanced breast cancer: clinical experience from a Belgian cooperative study. Breast Cancer Res Treat. 2008;109(1):59–65.

    Article  PubMed  Google Scholar 

  29. Steger GG, Gips M, Simon SD, et al. Fulvestrant (‘Faslodex’): clinical experience from the Compassionate Use Programme. Cancer Treat Rev. 2005;31(Suppl 2):S10–6.

    Article  CAS  PubMed  Google Scholar 

  30. Ciruelos E, Pascual T, Arroyo Vozmediano ML, et al. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. Breast. 2014;23(3):201–8.

    Article  PubMed  Google Scholar 

  31. Somlo G, Barlow W, Moore H, et al. Fulvestrant alone versus fulvestrant and everolimus versus fulvestrant, everolimus and anastrozole: a phase III randomized, placebo-controlled trial in postmenopausal patients with hormone-receptor-positive stage IV breast cancer: SWOG-Clinical Trials Initiative (CTI)* S1222 [abstract no. OT2-1-01]. In: San Antonio Breast Cancer Symposium; 2014.

  32. US National Institutes of Health. ClinicalTrials.gov. 2015. http://www.clinicaltrials.gov/. Accessed 9 June 2015.

  33. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530–5.

    Article  CAS  PubMed  Google Scholar 

  34. Robertson JF, Lindemann JP, Llombart-Cussac A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res Treat. 2012;136(2):503–11.

    Article  CAS  PubMed  Google Scholar 

  35. Robertson JFR, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: overall survival from the phase II ‘first’ study [abstract no. S6-04]. In: San Antonio Breast Cancer Symposium; 2014.

Download references

Acknowledgments

The manuscript was reviewed by: S. Saluja, Saran Ashram, Agra, India; R.B. Shah, Department of Pharmacology, GMERS Medical College and Hospital, Gandhinagar, Gujarat, India; G.G. Steger, Medical University of Vienna, Department of Internal Medicine I, Division of Oncology, Vienna, Austria. During the peer review process, the manufacturer of fulvestrant was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

Katherijne A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Fulvestrant in postmenopausal women with locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy: a guide. Drugs Ther Perspect 31, 323–328 (2015). https://doi.org/10.1007/s40267-015-0236-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-015-0236-7

Keywords

Search

Navigation